Literature DB >> 24249319

[Pitfalls in diagnosis and treatment of cutaneous larva migrans: three unusual cases from a dermatology clinic].

Maria Kitchen1, Manuel Wilhelm, Sabine Moser-Oberthaler, Reinhard Höpfl, Gudrun Ratzinger, Van Ahn Nguyen, Matthias Schmuth.   

Abstract

Cutaneous larva migrans (CLM, creeping eruption) is a skin disease commonly seen in travelers returning from the tropics. The lesions are caused by intradermal migration of animal hookworm larvae which cannot mature in humans. While the typical serpiginous skin lesions are easily diagnosed and treated with albendazole or ivermectin, unusual presentations can be misdiagnosed and cause prolonged morbidity. We present 3 cases of CLM, which were difficult to diagnose and/or treat.Case 1 is a 34-year old Caucasian male who presented with itchy papular lesions on the soles of both feet and was initially treated for plantar psoriasis.Case 2 is a 54-year old Caucasian male who suffered from extensive follicular larva migrans on the buttocks for several months and was only cured after repeated courses of albendazole and ivermectin.Case 3 is a 29-year old Caucasian male with pruritic inflammatory papules on the trunk. Despite extensive diagnostic procedures including skin biopsies and tissue cultures the correct diagnosis was only made later during the course of the illness. After treatment for CLM with albendazole (800 mg/d for 3 days) and after resolution of perifocal edema and inflammation the typical serpiginous tracks became more obvious. They responded rapidly to anthelminthic treatment.These cases highlight the importance of careful history taking and work-up in individuals presenting with atypical skin lesions. In case of exposure to CLM empiric anthelminthic treatment might be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24249319     DOI: 10.1007/s00508-013-0446-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  9 in total

1.  Effectiveness of a new therapeutic regimen with albendazole in cutaneous larva migrans.

Authors:  S Veraldi; G Rizzitelli
Journal:  Eur J Dermatol       Date:  1999 Jul-Aug       Impact factor: 3.328

2.  Treatment of larva migrans cutanea (creeping eruption): a comparison between albendazole and traditional therapy.

Authors:  G Albanese; C Venturi; G Galbiati
Journal:  Int J Dermatol       Date:  2001-01       Impact factor: 2.736

3.  Efficacy of albendazole ointment on cutaneous larva migrans in 2 young children.

Authors:  Eric Caumes
Journal:  Clin Infect Dis       Date:  2004-06-01       Impact factor: 9.079

Review 4.  Hookworm-related cutaneous larva migrans.

Authors:  Patrick Hochedez; Eric Caumes
Journal:  J Travel Med       Date:  2007 Sep-Oct       Impact factor: 8.490

5.  Cutaneous larva migrans in Hospital Kuala Lumpur, Malaysia: rate of correct diagnosis made by the referring primary care doctors.

Authors:  Felix Boon-Bin Yap
Journal:  Trans R Soc Trop Med Hyg       Date:  2011-05-19       Impact factor: 2.184

6.  Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin.

Authors:  O Bouchaud; S Houzé; R Schiemann; R Durand; P Ralaimazava; C Ruggeri; J P Coulaud
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

7.  Cutaneous larva migrans: clinical features and management of 44 cases presenting in the returning traveller.

Authors:  V Blackwell; F Vega-Lopez
Journal:  Br J Dermatol       Date:  2001-09       Impact factor: 9.302

8.  Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit.

Authors:  E Caumes; J Carrière; G Guermonprez; F Bricaire; M Danis; M Gentilini
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

9.  Cutaneous larva migrans in travelers: synopsis of histories, symptoms, and treatment of 98 patients.

Authors:  T Jelinek; H Maiwald; H D Nothdurft; T Löscher
Journal:  Clin Infect Dis       Date:  1994-12       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.